Spero Therapeutics, Inc.SPRONASDAQ
Loading
Other Income/Expenses (Net) Over TimeContracting
Percentile Rank80
5Y CAGR+31.5%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

5Y CAGR
+31.5%/yr
Long-term compound
Percentile
P80
Within normal range
vs 5Y Ago
3.9x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$3.27M-31.8%
2024$4.79M+22.2%
2023$3.92M+193.0%
2022$-4.22M-136.3%
2021$-1.78M-314.3%
2020$833000.00-63.6%
2019$2.29M+100.3%
2018$1.14M-38.0%
2017$1.84M+217.9%
2016$580000.00-